[
    [
        {
            "time": "",
            "original_text": "“20cm”涨停！芯片界“药明康德”半年报藏玄机",
            "features": {
                "keywords": [
                    "涨停",
                    "芯片",
                    "药明康德",
                    "半年报"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "半导体",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "“20cm”涨停！芯片界“药明康德”半年报藏玄机",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "中泰证券：维持药明康德(603259.SH)“买入”评级 产能快速扩张 有望驱动小分子CDMO业绩提速",
            "features": {
                "keywords": [
                    "中泰证券",
                    "药明康德",
                    "买入",
                    "CDMO",
                    "产能扩张"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券：维持药明康德(603259.SH)“买入”评级 产能快速扩张 有望驱动小分子CDMO业绩提速",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德(603259)：激励计划发布 库威基地收购落地 长期前景可期",
            "features": {
                "keywords": [
                    "药明康德",
                    "激励计划",
                    "库威基地",
                    "收购",
                    "长期前景"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德(603259)：激励计划发布 库威基地收购落地 长期前景可期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国金证券：维持药明康德(603259.SH)“买入”评级 国内CXO产业整体保持高景气",
            "features": {
                "keywords": [
                    "国金证券",
                    "药明康德",
                    "买入",
                    "CXO",
                    "高景气"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券：维持药明康德(603259.SH)“买入”评级 国内CXO产业整体保持高景气",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德(603259.)：板块高景气 CXO龙头加速成长",
            "features": {
                "keywords": [
                    "药明康德",
                    "CXO",
                    "高景气",
                    "龙头",
                    "成长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(603259.)：板块高景气 CXO龙头加速成长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德(603259)事件点评：激励加码 协同加深 持续看好",
            "features": {
                "keywords": [
                    "药明康德",
                    "激励",
                    "协同",
                    "看好"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德(603259)事件点评：激励加码 协同加深 持续看好",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝莱德减持药明康德(02359)98.14万股，每股作价约167.17港元 减持股份",
            "features": {
                "keywords": [
                    "贝莱德",
                    "减持",
                    "药明康德",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝莱德减持药明康德(02359)98.14万股，每股作价约167.17港元 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国金证券维持药明康德买入评级：板块高景气，CXO龙头加速成长",
            "features": {
                "keywords": [
                    "国金证券",
                    "药明康德",
                    "买入",
                    "CXO",
                    "高景气"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持药明康德买入评级：板块高景气，CXO龙头加速成长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天士力抗抑郁新药获批临试；海南博鳌全球特药险上线；正腾康生物完成B轮融资",
            "features": {
                "keywords": [
                    "天士力",
                    "抗抑郁",
                    "新药",
                    "博鳌",
                    "特药险",
                    "融资"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天士力抗抑郁新药获批临试；海南博鳌全球特药险上线；正腾康生物完成B轮融资",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "礼来最新财报：治疗阿尔茨海默病和糖尿病，两大潜在重磅药物计划今年递交上市申请（附PPT）",
            "features": {
                "keywords": [
                    "礼来",
                    "财报",
                    "阿尔茨海默病",
                    "糖尿病",
                    "药物",
                    "上市申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "礼来最新财报：治疗阿尔茨海默病和糖尿病，两大潜在重磅药物计划今年递交上市申请（附PPT）",
                "Correlation": 2,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "速递 | 32亿美元加码布局mRNA疫苗和疗法开发，赛诺菲收购新锐",
            "features": {
                "keywords": [
                    "赛诺菲",
                    "mRNA",
                    "疫苗",
                    "疗法",
                    "收购"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "速递 | 32亿美元加码布局mRNA疫苗和疗法开发，赛诺菲收购新锐",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "游戏产业将变天？北上积极调仓聚焦两大板块",
            "features": {
                "keywords": [
                    "游戏产业",
                    "北上",
                    "调仓",
                    "板块"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "游戏"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "游戏产业将变天？北上积极调仓聚焦两大板块",
                "Correlation": 1,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]